Kamada Announces Expansion of Plasma Collection Operations in Texas with the Opening of New Site in Houston

Core Points - Kamada Ltd. has opened a new plasma collection center in Houston, Texas, which is expected to have an annual collection capacity of approximately 50,000 liters and contribute estimated annual revenues of $8 million to $10 million at full capacity [1][3] - The Houston center will collect both normal source plasma and specialty plasma, including Anti-Rabies and Anti-D, and is anticipated to be one of the largest specialty plasma collection sites in the U.S. [1][2] - The company plans to submit a prior approval supplement to the FDA and a plasma master file to the EMA for the Houston site during the first half of 2025, with expected approval decisions within 9-12 months of submission [2][5] Company Overview - Kamada Ltd. is a global biopharmaceutical company focused on rare and serious conditions, with a portfolio of FDA-approved plasma-derived products [4] - The company operates a plasma collection center in Beaumont, Texas, and is expanding its operations with the new center in Houston and a planned third center in San Antonio, Texas, expected to open in the first half of 2025 [3][4] - Kamada's commercial products include six FDA-approved plasma-derived biopharmaceutical products and the company is also advancing an innovative development pipeline targeting significant unmet medical needs [4][5]